You are here

  • Home
  • Archive
  • Volume 14, Issue 7
  • Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer

Article metrics

Article menu
Oncology
Original research
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer

 

Online download statistics by month:

Online download statistics by month: July 2024 to June 2025

AbstractFullPdf
Jul 2024816828116
Aug 202430229640
Sep 202430230226
Oct 202431730726
Nov 202432030738
Dec 202429529615
Jan 20251038832
Feb 202515114727
Mar 2025535235
Apr 2025959138
May 2025838347
Jun 202514145
Total28512811445